(KFF Health News) FDA advises that the HeartMate II and HeartMate 3 left ventricular assist devices (LVADs) are under Class I recall due to long-term buildup causing obstructions on the outflow graft.

Abbott has launched a “first-of-its-kind” trial to identify advanced heart failure patients who could potentially benefit ...

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized ...

Table 2 shows the general characteristics of intermediate ... Thoratec Laboratories Corp., CA, USA), the HeartMate IP1000, VE and XVE (Thoratec Corp.), the Novacor (World Heart Corp., CA, USA ...

Abbott Laboratories (NYSE:ABT) recently experienced a 20% price increase over the last quarter. This uptick coincides with several noteworthy developments, including Abbott's collaboration with ...

The exit site requires meticulous, sterile dressing changes, initially 2 3 times a day, tapering to once a day after the site heals and the patient returns home. The driveline must be securely ...

The HeartMate 3™ LVAD is the most advanced LVAD ... the LVAD market was valued at $1.1 billion in 2023 and is projected to reach $2.4 billion by 2032. About Cadrenal Therapeutics, Inc. Cadrenal ...